Here are the DEF 14A proxy statements from Medtronic plc (MDT) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow MDT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MDT filings page.
Medtronic plc is asking shareholders at its October 15, 2026 Annual General Meeting in Galway, Ireland to vote on six key proposals, including electing twelve directors for one-year terms ending in 2027, ratifying PricewaterhouseCoopers LLP as independent auditor for fiscal 2027, approving executive compensation on an advisory basis, renewing the Board’s authority under Irish law to issue shares and to opt out of statutory pre-emption rights, and authorizing overseas market purchases of Medtronic ordinary shares. The Board recommends a “FOR” vote on all proposals.
For fiscal 2026, Medtronic generated $36.4 billion in revenue, up 8.4% reported and 5.8% organically versus fiscal 2025, with GAAP diluted EPS of $3.73 and non-GAAP diluted EPS of $5.53. GAAP operating profit rose 8.6%, non-GAAP operating profit rose 2.4%, and free cash flow reached $5.4 billion, the highest since 2022. Operating cash flow was $7.3 billion, and the company returned $4.2 billion to shareholders via dividends and net share repurchases.
Medtronic highlights strategic moves including the initial public offering of its Diabetes business, MiniMed, increased M&A and venture investments, and creation of new Board Growth and Operations Committees focused on portfolio, capital allocation, and margin improvement. The company reports serving over 82 million patients in FY26 and advancing sustainability, inclusion, and governance initiatives, with 17% female and 33% racial diversity among director nominees and an average director tenure of 7.42 years.